StockNews.AI
IDYA
StockNews.AI
204 days

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

1. IDEAYA will present at Oppenheimer's healthcare conference on Feb 11, 2025. 2. The company will also participate in Citi's oncology leadership summit on Feb 19, 2025. 3. A live audio webcast will be available on IDEAYA's investor relations site. 4. IDEAYA focuses on developing targeted therapeutics using molecular diagnostics. 5. They are leveraging synthetic lethality in precision medicine for cancer treatment.

4m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor events can boost investor confidence and awareness, similar to past events that led to positive stock movements.

How important is it?

The events provide visibility and credibility, which are critical for biotech companies' valuations.

Why Short Term?

Investor events can create immediate interest and potentially spike shares, seen in previous healthcare conferences.

Related Companies

IDYA
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Oppenheimer 35th Annual Healthcare Life Sciences ConferenceTuesday, February 11th, 2025 at 1:20 PM ET Citi's 2025 Virtual Oncology Leadership SummitWednesday, February 19th, 2025 at 12:00 PM ET A live audio webcast of the conference event, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 20, 2024. Investor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relations[email protected] SOURCE IDEAYA Biosciences, Inc.

Related News